Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

LOS ANGELES, CA / ACCESSWIRE / September 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

Tigris patient enrollment momentum continues reaching 72 The Company anticipates three additional trial sites to be activated in Q3 NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CORRECTION FROM SOURCE: Spectral Medical Inc. A correction from source is being issued with respect to the press release titled, Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing, released on September 7, 2023, at 7:00 am ET. There was an error in the third sentence of the second paragraph.

CORRECTION – Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing

LOS ANGELES , Sept. 7, 2023 /PRNewswire/ -- The Law Offices of Frank R.

BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit

Tigris patient enrollment momentum continues reaching 72 The Company anticipates three additional trial sites to be activated in Q3 NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX: EDT) (“Spectral” or the “Company”) is pleased to announce that it has closed its previously announced ”bought deal” private placement of 9.0% convertible unsecured senior notes due November 1, 2026 (the “Notes") of the Company at a price of US$1,000 per Note (the “Issue Price”) for aggregate gross proceeds of US$4,553,000 (the "Offering").

Spectral Medical Inc. Closes C$6.1 Million Bought Deal Convertible Note Financing

NEW YORK , Sept. 7, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International Inc. ("Baxter" or the "Company") (NYSE: BAX) of a class action securities lawsuit.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Baxter International Inc.(BAX) Investors of a Class Action Lawsuit and Upcoming Deadline

CEDARHURST, N.Y. , Sept. 6, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Baxter International Inc. (NYSE: BAX), if they purchased the Company's securities between May 12, 2022 and February 8, 2023, inclusive (the "Class Period").

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Baxter International Inc. - BAX

NEW YORK , Sept. 6, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Baxter International Inc..

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Baxter International Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 11, 2023 - (NYSE: BAX)

NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Baxter International Inc. ("Baxter" or the "Company") (NYSE: BAX).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baxter International Inc. - BAX

LOS ANGELES, CA / ACCESSWIRE / September 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

EARLY SEPTEMBER FINAL DEADLINE: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the "Class Period"), of the important September 11, 2023 lead plaintiff deadline.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Baxter International Inc. Investors With Losses to Secure Counsel Before Important September 11 Deadline in Securities Class Action - BAX

NEW ORLEANS , Sept. 1, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C.

BAXTER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Baxter International Inc. - BAX

LOS ANGELES, CA / ACCESSWIRE / September 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

AbbVie

Intuitive Surgical

Stryker

Medtronic

Med tech has been on the skids for no fault of its own. It's not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has normalized.

A Significant Reversal is in Sight for These 5 Med Tech Companies

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. José (Joe) E. Almeida, Baxter's chairman, president and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 13, 2024. About Baxter Every day, mil.

Baxter to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Although there has been a steady decline in the inflation rate in response to the Fed's aggressive rate hike plan, investors still have concerns about a potential rece

Will Baxter Stock Recover To Its Pre-Inflation Shock Highs?

NEW YORK , Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Baxter International Inc. (NYSE: BAX) alleging that the Company violated federal securities laws. Class Period: May 25, 2022 to February 8, 2023 Lead Plaintiff Deadline: September 11, 2023 No obligation or cost to you.

SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 11, 2023 in the Class Action Filed on Behalf of Baxter International Inc.(BAX) Shareholders

NEW YORK , Aug. 26, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baxter International Inc. (NYSE: BAX) between May 12, 2022 and February 8, 2023, both dates inclusive (the "Class Period"), of the important September 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Baxter securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Baxter International Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - BAX

NEW ORLEANS , Aug. 25, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 11, 2023 to file lead plaintiff applications in a securities class action lawsuit against Baxter International Inc. (NYSE: BAX), if they purchased the Company's securities between May 12, 2022 and February 8, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.

BAXTER SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Baxter International Inc. - BAX

BOSTON and NEW YORK , Aug. 24, 2023 /PRNewswire/ -- Advent International ("Advent"), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, today announced they have selected Franco Negron to be chief executive officer (CEO) of BioPharma Solutions (BPS) following its proposed divestiture from Baxter International Inc. (NYSE:BAX). The closing of the divestiture, which remains subject to the satisfaction of customary closing conditions, is currently expected to occur in the second half of 2023.

Advent International and Warburg Pincus Name Franco Negron CEO of BioPharma Solutions Following its Proposed Divestiture from Baxter

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023. José (Joe) E. Almeida, Baxter's chairman, president and chief executive officer is scheduled to present at 8:45 a.m. EST. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 5, 2024. About Baxter Every day, millions of patients and caregive.

Baxter to Present at 2023 Wells Fargo Healthcare Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Stephen (Steve) H. Rusckowski, former chairman, president and chief executive officer of Quest Diagnostics, Inc., to its board of directors. Effective today, Mr. Rusckowski serves on Baxter's Compensation and Human Capital, and Quality, Compliance and Technology Committees. In addition, the company has announced that Michael (Mike) Mahoney will be resigning from the.

Baxter Announces Updates to Its Board of Directors

LOS ANGELES, CA / ACCESSWIRE / August 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 25, 2022 and February 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 11, 2023.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Baxter International Inc. ("Baxter") (NYSE:BAX) between May 25, 2022 and February 8, 2023. If you suffered a loss, contact us at the link below.

BAX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Baxter International Inc.

NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International Inc. ("Baxter" or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter investors who were adversely affected by alleged securities fraud between May 25, 2022 and February 8, 2023.

BAX LAWSUIT ALERT: Levi & Korsinsky Notifies Baxter International Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Aug. 15, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Baxter International Inc. (NYSE: BAX) alleging that the Company violated federal securities laws. Class Period: May 25, 2022 to February 8, 2023 Lead Plaintiff Deadline: September 11, 2023 No obligation or cost to you.

BAX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 11, 2023 in the Class Action Filed on Behalf of Baxter International Inc. Shareholders

News for Baxter Stock (BAX)